Almirall

Pharmaceutical company

ALM Barcelona Stock Exchange ISIN ES0157097017 LEI 95980020140005007996
Follow Almirall Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €1.1B +12.4% vs prior year
Net income €46.2M +354.9% vs prior year
EPS, diluted €0.22 +340% vs prior year
Operating cash flow €174.5M +8.5% vs prior year
Revenue by fiscal year
€807.4M
€827.2M
€863.2M
€894.5M
€985.7M
€1.1B
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−€500M€0€500M€1B€1.5BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€1.1B€46.2M
FY24€985.7M€10.1M
FY23€894.5M−€38.5M
FY22€863.2M€4.3M
FY21€827.2M−€40.9M
FY20€807.4M€74.3M
MarginsShare of revenue
  • Operating margin
  • Net margin
−5%0%5%10%15%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY256.6%4.2%
FY243.7%1%
FY23−0.6%−4.3%
FY225.4%0.5%
FY210.7%−4.9%
FY2011.4%9.2%
Free cash flowOperating cash flow minus capital expenditure
€0€100M€200M€300MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25€139.5M
FY24€130.9M
FY23€60M
FY22€132.1M
FY21€215M
FY20€100.9M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€10M€20M€30MFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25€26.2M€1.3M
FY24€3.3M€539K
FY23€2.6M€157K
FY22€12.4M€46K
FY21€11.7M€596K
FY20€2.1M€82K
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Almirall
  • Healthcare median
−100%−75%−50%−25%0%25%FY20FY21FY22FY23FY24FY25
Show the numbers
YearAlmirallHealthcare median
FY254.2%−30.6%
FY241%−47%
FY23−4.3%−58%
FY220.5%−80.4%
FY21−4.9%−71.9%
FY209.2%−62.2%